These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2105541)

  • 1. Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat.
    Villani F; Galimberti M; Monti E; Cova D; Lanza E; Rozza-Dionigi A; Favalli L; Poggi P
    Toxicol Appl Pharmacol; 1990 Feb; 102(2):292-9. PubMed ID: 2105541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159).
    Herman EH; Ferrans VJ; Bhat HB; Witiak DT
    Cancer Chemother Pharmacol; 1987; 19(4):277-81. PubMed ID: 3594714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The prevention of the myocardial toxicity of doxorubicin with superoxide dismutase].
    Villani F; Galimberti M; Favalli L; Rozza A; Lanza E; Poggi P
    G Ital Cardiol; 1991 Jun; 21(6):633-41. PubMed ID: 1743445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat.
    Yeung TK; Jaenke RS; Wilding D; Creighton AM; Hopewell JW
    Cancer Chemother Pharmacol; 1992; 30(1):58-64. PubMed ID: 1586981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of doxorubicin-induced cardiomyopathy by reduced glutathione.
    Villani F; Galimberti M; Zunino F; Monti E; Rozza A; Lanza E; Favalli L; Poggi P
    Cancer Chemother Pharmacol; 1991; 28(5):365-9. PubMed ID: 1914080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats.
    Herman EH; el-Hage A; Ferrans VJ
    Toxicol Appl Pharmacol; 1988 Jan; 92(1):42-53. PubMed ID: 3124293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of superoxide dismutase and catalase on the delayed toxicity of doxorubicin].
    Villani F; Galimberti M; Poggi P; Rozza A; Lanza E; Favalli L; Scavini C
    Cardiologia; 1992 Oct; 37(10):709-11. PubMed ID: 1296877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment with ICRF-187 allows a marked increase in the total cumulative dose of doxorubicin tolerated by beagle dogs.
    Herman EH; Ferrans VJ; Young RS; Hamlin RL
    Drugs Exp Clin Res; 1988; 14(9):563-70. PubMed ID: 3147886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine.
    Herman EH; Ferrans VJ
    Lab Invest; 1983 Jul; 49(1):69-77. PubMed ID: 6408310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529.
    Agen C; Bernardini N; Danesi R; Della Torre P; Costa M; Del Tacca M
    Cancer Chemother Pharmacol; 1992; 30(2):95-9. PubMed ID: 1600601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of cardiotoxicity of a new anthracycline derivative: 4'-deoxy-4'-iodo-doxorubicin.
    Villani F; Galimberti M; Lanza E; Rozza A; Favalli L; Poggi P
    Invest New Drugs; 1988 Sep; 6(3):173-8. PubMed ID: 3192383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amelioration of chronic anthracycline cardiotoxicity by ICRF-187 and other compounds.
    Herman EH; Ferrans VJ
    Cancer Treat Rev; 1987 Dec; 14(3-4):225-9. PubMed ID: 3125968
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles.
    Herman EH; Ferrans VJ; Myers CE; Van Vleet JF
    Cancer Res; 1985 Jan; 45(1):276-81. PubMed ID: 3917371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat.
    Hirano S; Wakazono K; Agata N; Iguchi H; Tone H
    Drugs Exp Clin Res; 1994; 20(4):153-60. PubMed ID: 7813387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of trimetazidine on early and delayed doxorubicin myocardial toxicity.
    Perletti G; Monti E; Paracchini L; Piccinini F
    Arch Int Pharmacodyn Ther; 1989; 302():280-9. PubMed ID: 2636823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells.
    Shipp NG; Dorr RT; Alberts DS; Dawson BV; Hendrix M
    Cancer Res; 1993 Feb; 53(3):550-6. PubMed ID: 8425187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187.
    Zhang J; Herman EH; Ferrans VJ
    Am J Pathol; 1993 Jun; 142(6):1916-26. PubMed ID: 8506959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
    Alderton P; Gross J; Green MD
    Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs.
    Herman EH; Ferrans VJ; Young RS; Hamlin RL
    Cancer Res; 1988 Dec; 48(23):6918-25. PubMed ID: 3141049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modification of doxorubicin-induced cardiotoxicity: effect of essential fatty acids and ICRF-187 (dexrazoxane).
    Chakrabarti KB; Hopewell JW; Wilding D; Plowman PN
    Eur J Cancer; 2001 Jul; 37(11):1435-42. PubMed ID: 11435077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.